"Inhloso ukuthuthukisa izindlela zokwelapha zokuthuthukisa ukusebenza kwe-G3PP kubantu ukunciphisa imiphumela enobuthi kashukela futhi kubhekwane nembangela yezifo ezihlobene nokuguga ezihambisana noshukela ngokweqile kanye nokudla kwamafutha," kusho uDkt. Marc Prentki, Usosayensi Oyinhloko eNyuvesi yaseNyuvesi I-Montreal Hospital Research Centre kanye noMqondisi we-Montreal Diabetes Research Centre, ohola ucwaningo noDkt. SR Murthy Madiraju.
Ama-activators e-G3PP njengemithi yokwelapha izifo ze-cardiometabolic kanye nokukhuthaza ukuguga okunempilo athuthukiswa yi-Montreal biotech, i-NIMIUM Therapeutics, eholwa yi-CEO uDkt. Philippe Walker. I-Prentki isebenza njenge-CSO.
Ososayensi basebenzise imodeli yezikelemu ze-C. elegans, evamile ocwaningweni lokuguga, ukuze babonise ukuthi ukwanda komsebenzi we-G3PP kwandisa isikhathi sokuphila futhi kuthuthukisa kakhulu impilo yezilwane. Umsebenzi onyusiwe we-G3PP wehlise ukugcinwa kwamafutha futhi wavikeleka kushukela oweqile kanye nemithelela elimaza ingcindezi ye-oxidative. I-G3PP isebenza ngokuguqula i-glucose eyeqile ibe i-glycerol, engakhishwa kalula ngumzimba. I-G3PP iphinde yaboniswa ukuvikela amaseli e-beta akhiqiza i-insulin, alahlekelwa ukusebenza lapho i-glucose eningi ikhona.
Lolu cwaningo lusekelwe uxhaso oluvela eCanada Institutes of Health Research. Iqembu lalihlanganisa u-Elite Possik, umbhali wokuqala we-athikili, u-Clémence Schmitt, u-Anfal Al-Mass, u-Ying Bai, u-Laurence Côté, u-Johanne Morin, u-Heidi Erb, u-Abel Oppong, u-Wahab Kahloan, u-J. Alex Parker, u-SR Murthy Madiraju, no-Marc I-Prentki.
